These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1271 related articles for article (PubMed ID: 8616911)

  • 1. Treatment of metastatic malignant melanoma with cisplatin plus tamoxifen.
    Feliu J; González Barón M; Chacón JI; Espinosa E; Garrido P; Castro J; Escobar Y; Colmenarejo A; Jara C; García Girón C; Espinosa J; Ordóñez A
    Cancer Chemother Pharmacol; 1996; 38(2):191-4. PubMed ID: 8616911
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical experience of fotemustine, cisplatin and high dose tamoxifen in patients with metastatic malignant melanoma.
    Semb KA; Aamdal S; Bohmann T; Lucas C; Gerard B
    Melanoma Res; 1998 Dec; 8(6):565-72. PubMed ID: 9918419
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The addition of tamoxifen to dacarbazine and cisplatin in metastatic malignant melanoma. A phase II trial of the Southwest Oncology Group, (SWOG-8921).
    Flaherty LE; Liu PY; Mitchell MS; Fletcher WS; Walker MJ; Goodwin JW; Stephens RL; Sondak VK
    Am J Clin Oncol; 1996 Apr; 19(2):108-13. PubMed ID: 8610631
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A clinical trial of intravenous vinorelbine tartrate plus tamoxifen in the treatment of patients with advanced malignant melanoma.
    Feun LG; Savaraj N; Hurley J; Marini A; Lai S
    Cancer; 2000 Feb; 88(3):584-8. PubMed ID: 10649251
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Chemoimmunotherapy of advanced malignant melanoma: sequential administration of subcutaneous interleukin-2 and interferon-alpha after intravenous dacarbazine and carboplatin or intravenous dacarbazine, cisplatin, carmustine and tamoxifen.
    Atzpodien J; Lopez Hänninen E; Kirchner H; Franzke A; Körfer A; Volkenandt M; Duensing S; Schomburg A; Chaitchik S; Poliwoda H
    Eur J Cancer; 1995 Jun; 31A(6):876-81. PubMed ID: 7646914
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Chemo-/immunotherapy in advanced malignant melanoma: carboplatin and DTIC or cisplatin, dtic, bcnu and tamoxifen followed by immunotherapy with interleukin 2 and interferon alpha-2a].
    Kirchner HH; Atzpodien J; Poliwoda H
    Med Klin (Munich); 1996 Apr; 91 Suppl 3():44-9. PubMed ID: 8692119
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase II study of carmustine, dacarbazine, cisplatin, and tamoxifen in advanced melanoma: a Southwest Oncology Group study.
    Margolin KA; Liu PY; Flaherty LE; Sosman JA; Walker MJ; Smith JW; Fletcher WS; Weiss GR; Unger JM; Sondak VK
    J Clin Oncol; 1998 Feb; 16(2):664-9. PubMed ID: 9469356
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase II trial of biochemotherapy with interferon alpha, dacarbazine, cisplatin and tamoxifen in metastatic melanoma: a Southwest Oncology Group trial.
    Margolin KA; Liu PY; Unger JM; Fletcher WS; Flaherty LE; Urba WJ; Hersh EM; Hutchins LE; Sosman JA; Smith JW; Weiss GR; Sondak VK
    J Cancer Res Clin Oncol; 1999; 125(5):292-6. PubMed ID: 10359134
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tamoxifen modulation of cisplatin resistance in patients with metastatic melanoma. A biologically important observation.
    Mc Clay EF; Mc Clay ME; Albright KD; Jones JA; Christen RD; Alcaraz J; Howell SB
    Cancer; 1993 Sep; 72(6):1914-8. PubMed ID: 8364868
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A phase II study of tamoxifen combined with cisplatin-interleukin 2 and alpha-interferon in metastatic melanoma.
    Antoine EC; Rixe O; Vuillemin E; Benhammouda A; Borel C; Ghironzi GC; Mularoni E; Franks C; Auclerc G; Soubrane C
    Am J Clin Oncol; 1995 Oct; 18(5):421-4. PubMed ID: 7572760
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Randomized, double-blind, placebo-controlled trial comparing the response rates of carmustine, dacarbazine, and cisplatin with and without tamoxifen in patients with metastatic melanoma. National Cancer Institute of Canada Clinical Trials Group.
    Rusthoven JJ; Quirt IC; Iscoe NA; McCulloch PB; James KW; Lohmann RC; Jensen J; Burdette-Radoux S; Bodurtha AJ; Silver HK; Verma S; Armitage GR; Zee B; Bennett K
    J Clin Oncol; 1996 Jul; 14(7):2083-90. PubMed ID: 8683240
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The effect of tamoxifen and cisplatin on the disease-free and overall survival of patients with high risk malignant melanoma.
    McClay EF; McClay ME; Monroe L; Baron PL; Cole DJ; O'Brien PH; Metcalf JS; Maize JC
    Br J Cancer; 2000 Jul; 83(1):16-21. PubMed ID: 10883662
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A phase II study of high dose tamoxifen and weekly cisplatin in patients with metastatic melanoma.
    McClay EF; McClay MT; Monroe L; Jones JA; Winski PJ
    Melanoma Res; 2001 Jun; 11(3):309-13. PubMed ID: 11468521
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase II trial of tirapazamine combined with cisplatin in chemotherapy of advanced malignant melanoma.
    Bedikian AY; Legha SS; Eton O; Buzaid AC; Papadopoulos N; Coates S; Simmons T; Neefe J; von Roemeling R
    Ann Oncol; 1997 Apr; 8(4):363-7. PubMed ID: 9209666
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The evidence for tamoxifen and chemotherapy as treatment for metastatic melanoma.
    Rusthoven JJ
    Eur J Cancer; 1998 Jul; 34 Suppl 3():S31-6. PubMed ID: 9849407
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dacarbazine, nimustine hydrochloride, cisplatin and tamoxifen combination chemotherapy for advanced malignant melanoma.
    Yamazaki N; Yamamoto A; Wada T; Ishikawa M
    J Dermatol; 1999 Aug; 26(8):489-93. PubMed ID: 10487002
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Biochemotherapy with carmustine, cisplatin, dacarbazine, tamoxifen and low-dose interleukin-2 for patients with metastatic malignant melanoma.
    Su PJ; Chen JS; Liaw CC; Chang HK; Wang HM; Yang TS; Lin YC; Liau CT; Yang HY; Yeh KY; Ho MM; Chang NJ; Wang CH; Chang JW
    Chang Gung Med J; 2011; 34(5):478-86. PubMed ID: 22035892
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cisplatin, dacarbazine, and fotemustine plus interferon alpha in patients with advanced malignant melanoma. A multicenter phase II study of the Italian Cooperative Oncology Group.
    Daponte A; Ascierto PA; Gravina A; Melucci MT; Palmieri G; Comella P; Cellerino R; DeLena M; Marini G; Comella G;
    Cancer; 2000 Dec; 89(12):2630-6. PubMed ID: 11135225
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase II trial of subcutaneous interleukin-2, subcutaneous interferon-alpha, intravenous combination chemotherapy, and oral tamoxifen in the treatment of metastatic melanoma: final results of cancer biotherapy research group 94-11.
    Dillman RO; Soori G; Wiemann MC; Schulof R; Dobbs TW; Ruben RH; DePriest CB; Church C
    Cancer Biother Radiopharm; 2000 Oct; 15(5):487-94. PubMed ID: 11155820
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Temozolomide and cisplatin in avdanced malignant melanoma.
    Daponte A; Ascierto PA; Gravina A; Melucci M; Scala S; Ottaiano A; Simeone E; Palmieris G; Comella G
    Anticancer Res; 2005; 25(2B):1441-7. PubMed ID: 15865103
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 64.